Inclusion Criteria:

          1. Prior allogeneic hematopoietic cell transplant

          2. A diagnosis of locally-assessed, biopsy-proven EBV+ PTLD with a pathology sample
             available for central review

          3. Availability of appropriate partially HLA-matched and restricted tabelecleucel cell
             product

          4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score >= 3) systemic disease (using
             Lugano Classification response criteria) by positron emission tomography
             (PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable
             quality to the central radiology laboratory prior to Cycle 1 Day 1.

          5. Failure of rituximab for first-line treatment of PTLD. Note: Subjects with CD20
             negative disease are eligible to enroll without prior anti-CD20 therapy after failure
             of first-line treatment (reduction of immunosuppression is not considered first-line
             therapy) and discussion with the sponsor's medical monitor.

          6. Males and females of any age

          7. Eastern Cooperative Oncology Group (ECOG) performance status <= 3 for subjects aged >
             16 years; Lansky score >= 20 for subjects from birth to 16 years

          8. Underlying primary disease, for which the subject underwent transplant, is in
             morphologic remission

          9. Adequate organ function

               1. Absolute neutrophil count >= 500/µL, with or without cytokine support

               2. Platelet count >= 50,000/µL, with or without transfusion support; platelet count
                  < 50,000/µL but >= 20,000/µL, with or without transfusion support, is permissible
                  if the subject has not had Grade >= 2 bleeding in the prior 6 months (where
                  grading of the bleeding is determined per the National Cancer Institute's Common
                  Terminology Criteria for Adverse Events [CTCAE], version 5.0)

               3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total
                  bilirubin (TBILI) each < 3 x the upper limit of normal (ULN); however, ALT, AST,
                  and TBILI each <= 5 x ULN is acceptable if the elevation is considered by the
                  investigator to be due to PTLD involvement of the liver

               4. Creatinine < 3 x ULN

         10. Subject or subject's representative is willing and able to provide written informed
             consent

        Exclusion Criteria:

          1. Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate,
             or extracorporeal photopheresis

          2. History of central nervous system (CNS) PTLD

          3. Grade >= 2 graft-versus-host disease (GvHD) per the Center for International Blood and
             Marrow Transplant Research (CIBMTR) consensus grading system at enrollment

          4. Ongoing or recent use of a checkpoint inhibitor (eg, nivolumab, pembrolizumab,
             ipilimumab) within three drug half-lives from the most recent dose to Cycle 1 Day 1

          5. Active adenovirus viremia

          6. Need for vasopressor or ventilatory support

          7. Antithymocyte globulin or similar anti-T cell antibody therapy <= 4 weeks prior to
             Cycle 1 Day 1

          8. Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor
             (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI)
             within 8 weeks of Cycle 1 Day 1

          9. Pregnancy

         10. Female of childbearing potential or male with a female partner of childbearing
             potential unwilling to use a highly effective method of contraception

         11. Inability to comply with study-related procedures